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Abstract:
Cell cycle checkpoints ensure genome integrity and are frequently
compromised in human cancers. A therapeutic strategy being explored takes
advantage of checkpoint defects in p53 deficient tumors in order to sensitize
them to DNA damaging agents by eliminating Chk1-mediated checkpoint
responses. Using mouse models, we demonstrated that p21 is a key
determinant of how cells respond to the combination of DNA damage and
Chk1 inhibition (combination therapy) in normal cells as well as in tumors.
Loss of p21 sensitized normal cells to the combination therapy much more
than did p53 loss and the enhanced lethality was partially blocked by CDK
inhibition. In addition, basal pools of 21 (p53-independent) provided p53 null
cells with protection from the combination therapy. Our results uncover a
novel p53-independent function for p21 in protecting cells from the lethal
effects of DNA damage followed by Chk1inhibition. Since p21 levels are low in
a significant fraction of colorectal tumors, they are predicted to be particularly
sensitive to the combination therapy. Results reported in this study support
this prediction.

Introduction
When exposed to DNA damaging agents, eukaryotic cells die,
senesce or arrest their division cycles to allow time for DNA repair. The
p53 and Chk1 proteins mediate cell cycle arrest in the G1-, S -and G2phases of the cell division cycle under these conditions. p53
accomplishes this through transcriptional activation of downstream
targets including p21 (1) whereas Chk1 promotes the ubiquitinmediated proteolysis of the Cdc25A protein phosphatase (2-7). TP53 is
one of the most frequently mutated genes in human cancers and cells
lacking a functional p53 pathway are unable to arrest in the G1 phase
of the cell division cycle. p53 deficient tumor cells maintain their ability
to arrest in the S- and G2-phases of the cell division cycle due to Chk1
activity. However, they are compromised in their ability to sustain
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these arrests (1). Importantly, Chk1 inhibitors selectively potentiate
the cytotoxictiy of DNA damaging agents in tumor cells with
nonfunctional p53 (8). Treating p53 deficient tumor cells with a DNA
damaging agent or anti-metabolite followed by a Chk1 inhibitor causes
tumor cells to move through the S- and G2-checkpoints with DNA
damage and ultimately to die (9-13). Thus, combining Chk1 inhibitors
with agents that induce genotoxic stress represents a therapeutic
strategy to selectively target tumors with intrinsic checkpoint defects
while minimizing toxicity in normal cells. Importantly, lowering Chk1
levels with Chk1-specific siRNAs, induces bypass of both the S- and
G2-checkpoints in p53-deficient cells thereby phenocopying effects
observed with Chk1 inhibitors (4). These studies validate Chk1
therapeutic target for treating p53-deficient tumors.
While performing studies to evaluate the dependency of p53
status on cellular responses to the therapies that combine DNA
damage with Chk1 inhibitors, it became apparent that studies
published to date relied on tumor cells cultured either ex vivo or as
xenografts in rodents. Under these conditions, the individual
contributions made by p53 mutation to experimental outcome cannot
be directly assessed due to the plethora of additional uncharacterized
mutations and genomic alterations present in these established cell
lines. Furthermore, the transcriptional targets of p53 that protect cells
from bypassing checkpoints in the presence of DNA damage and Chk1
inhibition have not been identified. p53 maintains checkpoint
responses through transcriptional activation of several genes including
p21, 14-3-3σ and Gadd45 (14). p21 loss has been reported in a
majority of colon tumors (15) and silencing of 14-3-3 σ by methylation
has been reported in several cancers (16). Hence, it is important to
determine how cells lacking p53 effectors respond to DNA damage
coupled with Chk1 inhibition in order to understand which of these
targets play dominant roles in locking down the cell cycle in the
presence of DNA damage. To address these issues, we employed
genetically defined mouse models (wild type, p53 null, p21 null and
p53/p21 null mice) to assess whether DNA damage in combination
with Chk1 inhibition selectively kills cells that are null for p53 but
otherwise normal and to determine the role played by both basal and
p53-induced pools of p21 in this process. Advantages of knock-out
mouse models include the ability to study checkpoint control in vivo
and the ability to circumvent mutational heterogeneity associated with
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tumor cells. Our studies identified p53 status as a key determinant of
how cells with DNA damage respond to Chk1 inhibition and identified a
role for p21, both basal- and p53 induced-pools, in protecting normal
epithelial cells and colorectal tumors from the lethal effects of DNA
damage as a single stress or in combination with Chk1 inhibition.
These results indicate that p21 attenuators may sensitize tumors,
independent of their p53 status, to the lethal effects of DNA damage
combined with Chk1 inhibition.

Results
DNA damage induced by irinotecan is independent of
p53 status but enhanced by p21 loss.
To specifically address the contribution made by p53 or p21 loss
to the response of otherwise normal epithelial cells to the combination
of DNA damage and Chk1 inhibition, wild type (WT) and p53 null mice
were treated with vehicle (saline or DMSO); irinotecan (DNA damaging
agent); UCN-01 (Chk1 inhibitor); or the combination of irinotecan and
UCN-01. UCN-01 in combination with irinotecan is currently being
tested in clinical trials in patients with advanced malignancies (8, 17).
Irinotecan specifically damages S- phase cells by inducing single
strand breaks that ultimately give rise to double strand breaks during
the course of DNA replication. This leads to cell cycle arrest in the Sand G2-phases of the cell division cycle (18). Mice of 6 to 8 weeks of
age were used as this is prior to the time when p53 null mice exhibit
signs of lymphoma. We also focused on crypt epithelial cells of the
small intestine owing to their rapid cell division cycles. Irinotecan
treatment caused the accumulation of p53 (Fig. S1A) and p21 (Fig.
S1B) in crypt epithelial cells of WT mice. Irinotecan also induced the
accumulation of p53 in crypt epithelial cells of p21 null mice (Fig. S1A)
and p21 accumulation was shown to be p53-dependent (Fig. S1B).
DNA damage was assessed by monitoring for phosphorylation of
H2AX (γH2AX) since phosphorylation of this histone variant is one of
the earliest events observed in cells with DNA double strand breaks
(19). γH2AX staining was observed within the proliferating
compartment of crypts (Fig.1A) and at the base of the villi, which may
represent differentiating progenitors that experienced DNA damage as
they replicated in the crypt prior to their migration up into the villi
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(denoted by arrows in panel A). As seen in Fig. 1, γH2AX staining was
not detected in vehicle-treated controls. In contrast, ~ 42% of cells
stained positive for γH2AX in irinotecan-treated WT and p53 null mice.
Even higher levels of DNA damage were observed in small intestinal
epithelial cells of p21 null mice, with ~60% of cells staining positive for
γH2AX.
Mice were also treated with UCN-01 alone or in combination
with irinotecan and small intestines were isolated and analyzed for
γH2AX. UCN-01 induced a mild DNA damage response in cells derived
from WT and p53 null mice as ~ 2% of these cells stained positive for
γH2AX. This DNA damage response was not unexpected, as partial loss
of Chk1 has been shown to lead to DNA damage in other experimental
settings (20). However, in p21 null cells the percentage of γH2AX
positive cells increased to ~20% upon UCN-01 treatment. These data
demonstrate that the ability of irinotecan or UCN-01, as single agents,
to induce DNA damage in small intestinal epithelial cells is independent
of p53 status but enhanced by p21 loss. The number of γH2AX positive
cells was similar between cells treated with irinotecan alone or with
irinotecan followed by UCN-01 (Fig. 1B).

Combination therapy induces apoptosis in p53- and
p21-null cells.
Next, the ability of the combination therapy to cause epithelial
cells to undergo apoptosis was determined by examining small
intestinal crypts for the presence of either cleaved caspase-3 (Fig. 2)
or cleaved PARP (Fig. S1C). Apoptosis was not observed in crypt
epithelial cells from vehicle-treated WT or p53 null animals. An
occasional crypt epithelial cell was observed to undergo apoptosis in
vehicle treated p21 null mice. Irinotecan induced apoptosis in ~1 cell
per 2 crypts in mice that were WT for p53 (WT mice and p21 null
mice) but not significantly in p53 null mice. As a single agent, UCN- 01
did not induce apoptosis in WT or p53 null cells but a small number of
p21 null cells were consistently observed to undergo apoptosis in
vehicle and UCN-01 treated animals (Fig. 2B). Importantly, the
combination therapy was able to induce apoptosis of p53 null cells and
the effects were even more striking in p21 null cells. We also tested a
second more selective Chk1 inhibitor, AZD7762 (13) for its ability to
potentiate the effects of irinotecan in p53 and p21 null crypt epithelial
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cells. As seen in Fig. S1D, AZD7762 had some activity as a single
agent but greatly enhanced the ability of irinotecan to induce crypt
epithelial cells lacking either p53 or p21 to undergo apoptosis.

Bypass of DNA damage checkpoint in cells null for
either p53 or p21.
It has been proposed that DNA damage coupled with Chk1
inhibition induces cells to bypass DNA damage checkpoints resulting in
mitotic catastrophe and cell death. Therefore, we monitored the ability
of irinotecan to induce cell cycle arrest and UCN-01 to abrogate this
arrest. Irintoecan was expected to arrest cells in the S and G2 phases
of the cell division cycle thereby reducing BrdU incorporation and
leading to higher levels of Geminin, a protein specifically expressed in
the S- and G2-phases of the cell cycle (21). In addition levels of
phosphorylated histone H3 (phistone H3) a mitotic marker (22, 23)
were expected to be lower in cells with DNA damage due to G2 cell
cycle arrest. Crypt epithelial cells of the small intestines have a high
proliferative index in vehicle- treated animals, ~35-40% of cells
stained positive for BrdU (Fig. S2) and Geminin (Fig. 3A). As expected,
there was significant increase in the number of Geminin positive cells
(Fig. 3A) as well as a significant decrease in both the number of BrdU
positive (Fig. S2) and phistone H3 positive (Fig. 3B, C) cells in
irinotecan-treated mice, indicative of cell cycle arrest. However,
irinotecan was less effective at inducing cell cycle arrest in p21 null
cells compared to WT and p53 null cells, as shown by the higher
percentage of p21 null cells staining positive for BrdU (Fig. S2) and
phistone H3 (Fig. 3B, C) in the presence of DNA damage. At baseline,
there were 50% more p21 null cells that stained positive for phistone
H3 compared with WT and p53 null cells (Fig. 3B, C). The higher
mitotic index in intestinal epithelial cells lacking p21 indicates that p21
loss perturbs normal cell cycle regulatory circuits.
It was predicted that when UCN-01 was administered to
irinotecan-treated animals, checkpoint bypass would be observed in
p53 null but not p53 WT cells resulting in a reduction in Geminin
staining coincident with an increase in phistone H3 staining. As seen in
Fig. 3, checkpoint bypass was observed in p53 null but not WT cells.
Interestingly, p21 null cells were even more sensitive than p53 null
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cells to the combination treatment as indicated by the higher numbers
of phistone H3 staining cells (Fig. 3B, C).
We next asked whether there was a coincidence of checkpoint
bypass and apoptosis in p53 null cells exposed to the combination
therapy. This was accomplished by looking for crypt epithelial cells
that co-stained for both phistone H3 and cleaved caspase-3 (Fig. S3A,
B). ~ 2% of epithelial cells in crypts of p53 null mice and 8% in crypts
of p21 null mice stained positive for both phistone H3 and cleaved
caspase-3 indicating that these cells bypassed the G2 DNA damage
checkpoint, entered into mitosis and engaged the apoptotic pathway
(Fig. S3B). However, there were many more cleaved caspase 3
positive cells than phistone H3 positive cells, suggesting that either
apoptosis occurred independent of checkpoint bypass in these cells or
that the timing of organ harvest was not optimal to capture co-stained
cells.

Cdk activation is required for combination therapy to
induce checkpoint bypass and apoptosis.
Next, the phosphorylation status of Cdk1/2 was examined in
lysates prepared from the small intestines of treated animals (Fig. 4A).
Tyrosine 15-phosphorylation (pY15) inhibits the enzymatic activity of
Cdk1/2 (24) and therefore can be used to indirectly assess Cdk activity
under a variety of conditions. As expected pY15 levels increased upon
irinotecan-treatment in each genotype, indicative of Cdk inhibition in
response to DNA damage (lanes 2, 6, 10) and Cdk1/2 became partially
dephosphorylated on Y15 when mice were subsequently treated with
UCN-01 (lanes 3, 7, 11). This was an expected result because UCN-01
inhibits Chk1 causing Cdc25A phosphatase levels to rise resulting in
Cdk1/2 dephosphorylation (4). Although the combination treatment
resulted in Cdk1/2 dephosphorylation in all cases, checkpoint bypass
and apoptosis were only observed in crypt epithelial cells lacking p53
or p21 (Fig. 2, 3). Next, experiments were carried out to determine if
Cdk activity is needed in order for the combination therapy to induce
apoptosis (Fig. 4B, C). This was accomplished by treating mice with
purvalanol A, a potent Cdk inhibitor (25). A reduction of the number of
mitotic cells was observed in the small intestines of purvalanol Atreated mice demonstrating that the drug was bioavailable (Fig. S3C,
D). Mice were subjected to the combination therapy followed by
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treatment with either vehicle or purvalanol A and small intestinal
crypts were examined for cleaved caspase 3. There was a significant
decrease (~50%) in the number of apoptotic (Fig. 4B, C) crypt
epithelial cells in purvalanol A treated animals compared with vehicle
treated controls. Thus, the combination treatment induced checkpoint
bypass and apoptosis, at least in part, through Cdk activation.

Loss of p21 enhances combination treatment induced
apoptosis in cells lacking p53.
Crypt epithelial cells null for p21 but wild-type for p53 exhibited
a robust apoptotic response to the combination therapy (Fig. 2)
relative to p53 null cells that retained basal pools of p21. As expected,
p21 was not induced by DNA damage in the absence of p53 (Fig S1B).
The enhanced sensitivity of p21 null cells relative to p53 null cells to
the combination therapy led us to ask if p53-independent (basal) pools
of p21 played a role in protecting cells from the lethal effects of the
combination therapy. To do this, double knockout mice lacking both
p21 and p53 were treated with vehicle, irinotecan, UCN-01 or the
combination therapy (Fig. 5 and Fig. S4A-C). Approximately 50% of
vehicle- treated cells stained weakly for γH2AX indicating a significant
amount of DNA damage in the absence of exogenous genotoxic and
irinotecan treatment increased both the number and intensity of
γH2AX positive cells (Fig. 5A, B and Fig. S4A, B). As expected, levels
of tyrosine-phosphorylated Cdk rose in cells of irinotecan-treated
animals and fell in cells of mice treated with either UCN-01 alone or
the combination therapy (Fig. 5C). These results demonstrated that
the Chk1 pathway was active in these cells and the drugs were
bioavailable in the small intestinal crypts of p53/p21 null animals.
Similar to p21 null cells, irinotecan treatment did not significantly
reduce BrdU incorporation (Fig. S4C, D) in p53/p21 double null cells,
suggestive of intrinsic checkpoint defects in these cells. Importantly,
the combination therapy induced checkpoint bypass in p53/p21 double
null cells as evidenced by the increase in the number of mitotic cells
observed in cells exposed to the combination treatment compared with
cells exposed to irinotecan alone (Fig 5D, E). In addition, the
combination therapy was capable of driving p53/p21 double null cells
into apoptosis (Fig. 5F, G) but not to the same degree as that
observed in cells null for p21 but WT for p53 (Fig. 2B). These results
demonstrated that both p53- dependent and -independent
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mechanisms operate to induce apoptosis under these conditions and
that p53-independent mechanisms were significantly enhanced in the
absence of basal pools of p21. These results reinforce the conclusion
that basal pools (p53 independent) of p21 provide a protective
function in p53 null cells.

Loss of p21 enhances ability of combination therapy to
drive p53 deficient colorectal tumor cells into apoptosis
Taken together, our results suggested that p21 deficient (p53
proficient) cells should be more susceptible to cell killing by
combination therapies than p53-deficient (p21 proficient) cells. To test
this and to determine the therapeutic efficacy of our findings, we
employed an orthotopic colon cancer model whereby parental and
mutant HCT116 tumor cells (1) were implanted directly into the cecum
of immunocompromised mice as described previously (26). Prior to
establishing the orthotopic xenografts, parental and p53 null HCT116
cells were transfected with plasmids expressing control (Ctrl) shRNAs
or p21-specific shRNAs followed by selection in puromycin. Although
HCT116 cells null for p21 have been reported (27), we detected
endogenous p21 in these cells both at the protein and mRNA levels
(data not shown). As seen in Fig. 6A, parental HCT116 cells
transfected with Ctrl shRNAs maintained an intact p53 DNA damage
signaling pathway as indicated by the accumulation of p53 and p21
upon UV-treatment. We were able to achieve knockdown (KD) of p21
in p53 null HCT116 cells (Fig. 6B, lane 3). Interestingly, when parental
HCT116 cells (p53 WT) were knocked down for p21 and selected in
puromycin, we observed a concurrent loss of p53 protein (Fig. S4E).
This was not observed in parental HCT116 cells transiently transfected
with plasmids encoding p21-specific shRNAs (Fig. S4F). Thus, p53
expression was selected against in HCT116 tumor cells lacking p21
function and as a result we were unable to obtain HCT116 cells that
were WT for p53 but knocked down for p21.
Next, HCT116 cells (parental, p53 null and p53 null/p21 KD)
were engineered to express a reporter gene encoding click beetle red
luciferase, cells were implanted into the cecum of recipient mice and
bioluminescence imaging was employed to demonstrate successful
implantation of tumor cells (Fig. 6C). Mice were then exposed to either
vehicle, irinotecan, AZD7762 (selective Chk1 inhibitor) or the
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combination of irinotecan and AZD7762. Tumors were removed and
analyzed for phistone H3 (Fig. 6D) and cleaved caspase 3 (Fig. 6E, F).
A significant increase in phistone H3 staining was observed in p53 null
and p53 null/p21 KD cells compared to parental cells following
exposure to the combination therapy. This indicates that cells deficient
in p53 or both p53 and p21 bypassed the G2 DNA damage checkpoint.
The combination therapy induced significantly more apoptosis in cells
lacking both p53 and p21 compared with control and p53 null cells
(Fig. 6E, F). Finally, p21 levels were restored in p53 null/p21 KD
HCT116 cells, cells were implanted into the cecum of recipient mice
and mice were treated as outlined above. As seen in Figure S5,
restoration of p21 in p53 null/p21 KD cells significantly reduced their
sensitivity to the combination therapy. These results validated the
specificity of the p21-shRNA and confirmed that basal pools of p21
provide partial protection to p53-deficient tumor cells from the lethal
effects of therapies that combine DNA damage with Chk1 inhibition.

Discussion
The development of anti-cancer regimens that take advantage
of the molecular differences between normal and cancer cells is highly
desirable. TP53 is one of the most frequently mutated genes in human
cancers and, as such, there is great interest in finding anti-cancer
regimens that selectively target p53 deficient tumors. Importantly,
Chk1 inhibitors such as UCN-01 and AZD7762 selectively potentiate
the cytotoxicity of DNA damaging agents in tumor cells with
nonfunctional p53 (11, 13, 28) and are currently being tested in
several clinical trials (8). In our study, we circumvented the
heterogeneity of transformed cells, and used mouse models to address
the contribution made by loss of p53 and its effector p21 in sensitizing
cells to the combination of DNA damage and Chk1 inhibition.
Irinotecan as a single agent induced 10 fold more apoptosis of small
intestinal epithelial cells in WT animals compared with cells from p53
null animals. This was in spite of the fact that levels of DNA damage
induced by irinotecan were similar in WT and p53 null cells. Whereas
irinotecan as a single agent was ineffective at driving p53 null cells
into an apoptotic cell death, we found that treatment with Chk1
inhibitors was capable of enhancing apoptosis in response to irinotecan
in these cells. This result unequivocally demonstrated that p53 is a
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significant determinant of how cells respond to DNA damage followed
by Chk1 inhibition.
Intriguingly, crypt epithelial cells lacking p21 sustained more
DNA damage than their WT or p53 null counterparts following
exposure to irinotecan and were more susceptible to cell killing by the
combination therapy. Given the large number of p53- regulated genes,
it was not necessarily expected that the loss of a single target (p21)
would have such a profound effect. These results demonstrated that
Chk1 together with p53, largely through its downstream effector p21,
protects crypt epithelial cells from the DNA damaging effects of
irinotecan. In addition, this study demonstrates that p53- independent
(basal) pools of p21, together with Chk1, protect crypt epithelial cells
from the DNA damaging effects of irinotecan. Rodriguez et al. (2006)
reported that HCT116 cells lacking p21 were sensitive to the
combination of excess thymidine and Chk1 inhibition and they noted
that p21 is induced when Chk1 is inhibited independent of p53 status.
However, their study did not test the importance of p21 induction in
p53 null cells by deleting it nor did they investigate the mechanism of
cell death. Here we report the consequences of deleting p21 (in p53
null mice) and knocking down p21 (in p53 null tumor cells).
Our results demonstrated that basal pools of p21 (p53independent) protected crypt epithelial cells from the DNA damaging
effects of irinotecan as both p21 null and p21/p53 null cells exhibited
higher levels of DNA damage following exposure to irinotecan than did
cells from WT animals or cells from mice that were null for p53 but WT
for p21 (Fig1B, 5A). Despite similar levels of DNA damage, a higher
fraction of crypt epithelial cells null for p21 (p53 WT) underwent
apoptosis compared with crypt epithelial cells null for both p21 and
p53. This suggests that tumors that are proficient in p53 signaling and
have low levels of p21 will be the most susceptible to combination
therapies that combine DNA damage with Chk1 inhibition due to their
ability to induce p53-dependent and -independent forms of apoptosis.
In addition, apoptosis observed in treated cells null for both p53 and
p21 was higher than that that observed in treated cells null for p53 but
WT for p21. Thus, combining p21 antagonists with the combination
therapy (DNA damage and Chk1 inhbition) is expected to further
sensitize p53 deficient tumors to the combination therapy.
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p21 has many functions that might explain how p53independent pools protect cells from the genotoxic effects of DNA
damaging agents and Chk1 inhibitors. p21 inhibits cell cycle
advancement by binding to and inhibiting CDKs (15). In addition to
regulating cell cycle progression, p21 binds to proliferating cell nuclear
antigen (PCNA), a DNA polymerase δ processivity factor, thereby
blocking processive DNA synthesis (29). The cytoplasmic pool of p21
has been shown to regulate apoptosis by binding to and inhibiting the
activity of proteins that induce apoptosis, including procaspase 3,
caspases 8 and 10, and the protein kinases SAPK and ASK1 (30).
Paradoxically, low levels of p21 promote assembly of cyclin D-CDK4/6
complexes and in this capacity has a positive role in promoting cell
cycle advancement (31). In order to distinguish between the these
diverse functions of p21 (Cdk regulator versus apoptotic regulator), we
treated mice with the Cdk inhibitor purvalanol A. Results demonstrated
that p21 exerts its protective effect, at least in part, through its ability
to inhibit Cdk activation (Fig. 4C).
We also observed that crypt epithelial cells that were null for
p53 but otherwise normal exhibited more modest apoptotic responses
to the combination therapy than did p53 deficient cancer cells. In
addition, experiments performed with a variety of cultured p53deficient tumor cells have reported 50 to 100 fold more cell death with
the combination therapy than with the DNA damaging alone (18, 32,
33). We measured a ~10 fold difference in the number of p53 null
small intestinal epithelial cells undergoing apoptosis in response to the
two treatment regimens. The differential response of non- transformed
p53 mutant epithelial cells compared with transformed p53 mutant
tumor cells to the combination therapy may be due to oncogenic stress
present in p53 mutant tumor cells. Oncogenic stress activates the
ATR/Chk1 pathway (34-36) and tumor cells depend on this signaling
pathway to maintain some semblance of genome stability (37).
HCT116 cells, used in this study, contain homozygous mutations in the
mismatch repair gene hMLH1 and this may also contribute to their
sensitivity to the combination therapy. Thus, the differential response
of p53 mutant normal cells versus p53 mutant tumor cells was likely
due to the presence of additional mutations present in tumor cells that
make them more vulnerable to cell death when subjected to DNA
damage followed by Chk1 inhibition and points to the usefulness of
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this therapeutic strategy in treating cancers lacking a functional p53
pathway.
In conclusion, this study demonstrates that p21 status is a
significant determinant of how cells with DNA damage respond to Chk1
inhibition and that p21 provides a protective effect in response to
combination therapies, in both p53 proficient and deficient
backgrounds. A major debilitating side effect of chemotherapy is GItoxicity. Here we show that p21 protects intestinal epithelium from the
toxicity associated with DNA damage and that Chk1 inhibition
sensitizes p21 deficient tumors to DNA damaging agents. This is
expected to provide a therapeutic window that facilitates killing of p21
deficient tumor cells while at the same time limiting G1 toxicity.

Materials and Methods
Additional information for the methods and materials used can
be found in Supplemental Methods.
All animal experiments described in this study were carried out
in strict accordance with the guidelines recommended for care and use
of laboratory animals by the National Institutes of Health (NIH, USA).
The Animal Studies Committee at Washington University (St. Louis)
approved all animal protocols used in this study.

Genotyping Trp53, Cdkn1a [p21WAF1/CIP1] mutant mice
Trp53 mutant mice (B6.129S2-Trp53tm1T4j/J, stock # 002102)
and Cdkn1a mutant mice (B6;129S2-Cdkn1atm1Tyj/J, stock# 003263)
were obtained from The Jackson Laboratory. 6 to 8 week old
Trp53+/+Cdkn1a+/+ (Wild type-WT), Trp53-/- littermates and Cdkn1a-/mice were used in this study. The Trp53+/- mutant mice and Cdkn1a-/mice were bred to generate the double knockout mice (Trp53-/Cdkn1a-/-). 6-14 week old Trp53-/- Cdkn1a-/- mice were used in this
study.

Treatment regimen
Drugs and vehicles were administered to mice via an
intraperitoneal (IP) route. Vehicle treated mice received 0.9% saline
on Day 1; 24h later (Day 2) they received 30% dimethyl sulphoxide
(DMSO) and were sacrificed 6h later. For single drug treatments, mice
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were injected with either 100 mg/kg irinotecan (Hospira, diluted in
saline) and sacrificed 24h later, or 5 mg/kg UCN-01 (Sigma, dissolved
in 30% DMSO) and sacrificed 6h later. For the combination treatment,
mice were injected with 100 mg/kg irinotecan on Day 1; 24h later
(Day 2) they received 5 mg/kg UCN-01 and were sacrificed 6h later.
To inhibit Cdk1 in vivo, mice received 100 mg/kg irinotecan on Day 1;
24h later (Day 2) they were injected with 5 mg/kg UCN-01; 1h after
receiving UCN-01, mice were injected with 68 mg/kg purvalanol A
(Tocris) or vehicle (PEG400: DMSO 50:50) and sacrificed 5h later (Fig
4C). To ensure the bioavailability of purvalanol A and its ability to
inhibit intestinal cell proliferation, animals were injected with two
doses of the drug. 68 mg/kg purvalanol A or vehicle (PEG 400: DMSO
50:50) was injected followed by a second dose of purvalanol A (34
mg/kg) or vehicle 1.5h later and sacrificed 1h after the second dose
(Fig S3C). The second dosing was administered because the half-life of
purvalanol A in mice is ~1h (38). For AZD7762 treatment, mice
received either 20 mg/kg AZD7762 (Axon Medchem) or vehicle
(11.3% 2-hydroxypropyl-β- cyclodextrin diluted in saline) and were
sacrificed 5h later. For the combination treatment, mice were injected
with 100 mg/kg irinotecan on Day 1, and 24h later (Day 2) they were
injected with 20 mg/kg AZD7762 and sacrificed 5h later.

Immunohistochemistry (IHC) and immunofluorescence
(IF)
All paraffin embedded intestinal sections were incubated with
the following antibodies: serine139 phosphorylated H2AX (γH2AX, Cell
Signaling Technology), Geminin (Santa Cruz), BrdU (Serotec), serine
28 phosphorylated histone H3 (Sigma-Aldrich), cleaved caspase-3 and
cleaved PARP (Cell Signaling Technology). To assay for BrdU
incorporation, mice were injected with BrdU (Amersham) according to
the manufacturer’s recommendations (2 ml per 100 g body weight)
and sacrificed 30 min later.

Cell culture and transfection
Parental and p53 null HCT116 cells (human colon carcinoma
cells) were transfected with a pcDNA plasmid expressing Click Beetle
Red Luciferase (CBRluc) reporter linked to EGFP. Clones stably
transfected with CBRluc-EGFP were selected by screening for zeocin
(Invitrogen) resistance. CBRluc-EGFP expressing parental and p53 null
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HCT116 cells were transfected with pLKO.1 vector expressing either a
p21 targeted shRNA or control shRNA directed against firefly luciferase
(provided by the RNAi consortium of Broad institute and Children's
discovery institute at Washington University). Stably transfected
clones were selected by screening for puromycin (Invitrogen)
resistance. To ensure stable knockdown, cells expressing p21 shRNA
or control shRNA were screened by Western blotting.

Implantation and treatment of orthotopic colon tumors
For establishing orthotopic colon tumors, 1.3 x 106 cells were
resuspended in 30 µl DMEM culture medium (GIBCO) and injected into
the cecal wall of immunocompromised NOD/SCID gamma mice (The
Jackson Laboratory, NOD.Cg- Prkdcscid Il2rgtm1Wjl/SzJ stock#
005557). Bioluminescence imaging was performed on days 3 and 7
post injection to monitor success of tumor implantation and growth.
Bioluminescent images were acquired using the IVIS Lumina (Caliper).
Images were analyzed using LivingImage software (Xenogen). Seven
to nine days post implantation; mice were subjected to the following
treatment schedule: t = 0h (Day 1) vehicle/irinotecan; t = 18h (Day
2) vehicle/AZD7762; t = 26h (Day 2) vehicle/AZD7762; t = 50h (Day
3) vehicle/irinotecan; t = 68h (Day 4) AZD7762/vehicle and mice were
sacrificed at t = 73h (Day 4). The following drug doses were used: 100
mg/kg irinotecan and 25 mg/kg AZD7762. 0.9% saline and 11.3% 2hydroxypropyl-β-cyclodextrin diluted in saline were used as the vehicle
controls for irinotecan and AZD7762, respectively.

Microscopy
For IHC analysis, images were captured using an Olympus BX51
microscope carrying an Olympus DP-71 camera. Images were
processed using DP-BSW software (Olympus). For analysis of IF
staining, images were captured using an Olympus BX-61 microscope
carrying a digital camera (C10600, Hamamatsu). Fluorescent images
were processed using Microsuite Biological Suite analysis software
(Olympus).

Western blotting
Intestines were isolated from treated mice and processed as
described in supplemental methods. 150 µg of total protein from
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intestinal lysates were loaded in each lane and probed with the
following antibodies: tubulin (1:1000, Sigma-Aldrich), p53 (1:500,
Leica Microsystems), GAPDH (1:2000, Imgenex), p21 (F-5, 1:1000,
Santa Cruz), phospho- Cdk1 Tyrosine 15 (1:750, Santa Cruz), and
Cdk1-total (1:750, Santa Cruz). For Western blotting using HCT116
cell lysates, the following antibodies were used: p53 (sc-126, 1:1000,
Santa Cruz), p21 (1:500, BD Biosciences,), tubulin (1:2500, Cell
Signaling Technology), actin (1:6000, Sigma), GAPDH (1:4000,
Imgenex).
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Figure legends
Figure 1. DNA damage induced by irinotecan is independent of p53
status but enhanced by p21 loss. (A) Small intestinal crypts isolated from
wild-type (WT), p53 null and p21 null mice that had been subjected to the
indicated treatments were examined by IHC for γH2AX (brown) and nuclei
were counterstained with hematoxylin (blue). Scale bar =100 µM. Arrows
indicate γH2AX positive cells that migrated up into the villi. (B) γH2AX
positive nuclei were counted in images similar to those shown in panel A.
Three mice were evaluated for each treatment group and a total of 250-400
crypt nuclei were scored per treatment group. Data are presented as mean
+/- SEM. Asterisks indicate significantly different using one-way ANOVA. *p
between 0.01 and 0.05; **p between 0.01 and 0.001; ***p< 0.001.
Statistical significance for comparisons between irinotecan and the
combination treatment across genotypes is indicated in Table S1.
Figure 2. Loss of p53 or p21 sensitizes crypt epithelial cells to
combination therapy. (A) Small intestinal crypts isolated from treated wildtype (WT) mice or mice null for either p53 or p21 were examined by IHC for
cleaved caspase-3 (CC3) (brown) and nuclei were counterstained with
hematoxylin (blue). Scale bar =100 µM. (B) The number of cells staining
positive for CC3 was determined in a total of 50 crypts per treatment group
(n = 3 to 5 mice per treatment group). Data are presented as mean +/- SEM.
Asterisks indicate significantly different using a one way ANOVA. **p between
0.01 and 0.001, ***p < 0.001. Statistical significance for comparisons
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between irinotecan and the combination treatment across genotypes is
indicated in Table S1.
Figure 3. Combination treatment induces checkpoint bypass in crypt
epithelial cells null for p53 or p21. (A) Small intestinal crypts isolated
from treated wild-type (WT) mice or mice null for either p53 or p21 were
examined for Geminin by immunofluorescent staining. Right panel illustrates
Geminin positive cells in small intestinal crypts of irinotecan treated WT mice.
Geminin (green); nuclei (blue, DAPI). Scale bar = 50 µM. Percentage of crypt
epithelial cells staining positive for Geminin was determined by scoring 200 to
300 nuclei per mouse (n = 3 to 5 mice per treatment group). Data are
presented as mean +/- SEM. Asterisks indicate significantly different as
determined by a one-way ANOVA. *p between 0.01 and 0.05; **p between
0.01 and 0.001; ***p< 0.001. Significant difference was also observed
between the combination treatments for WT compared to p53 null with p<
0.001and WT compared to p21 null with p< 0.001 (B) Small intestinal crypts
isolated from treated mice were stained for phosphohistone H3 (pHH3) and
the number of pHH3 positive cells per 75 crypts per mouse (n = 3 to 4 mice
per treatment group) was determined (panel C). pHH3 (red); nuclei (blue,
DAPI). Scale bar = 200 µM. Data are presented as mean +/- SEM. Asterisks
indicate significantly different by a one-way ANOVA. *p between 0.01 and
0.05; **pbetween 0.01 and 0.001; ***p< 0.001. Statistical significance for
pHH3 comparisons between irinotecan and the combination treatment across
genotypes is indicated in Table S1.
Figure 4. Effects of Cdk inhibition on ability of combination therapy to
induce checkpoint bypass and apoptosis in crypt epithelial cells
lacking p21 or p53. (A) Small intestines were isolated from treated WT mice
(lanes 1-4), p53 null (lanes 5-8) and p21 null mice (lanes 9-12), and
analyzed by Western blotting for Cdk1 (total levels), Cdk1 phosphorylated on
tyrosine 15 (pY15) and tubulin. (B) Small intestinal crypts isolated from
treated mice were examined for cleaved caspase-3 (CC3) (brown) and nuclei
were counterstained with hematoxylin (blue) by IHC. Scale bar = 50 µM. (C)
Cells staining positive for CC3 were counted in 50 crypts per mouse per
treatment group (3 to 4 mice per treatment group). Data are presented as
mean +/- SEM. Asterisks indicate significantly different using a two-tailed Ttest. *p between 0.01 and 0.05, ***p < 0.001.
Figure 5. Basal levels of p21 levels protect small intestinal epithelial
cells from lethal effects of combination therapy. (A) Small intestinal
crypts isolated from treated mice null for both p53 and p21 were examined by
IHC for γH2AX (brown) and nuclei (hematoxylin, blue). Scale bar = 50 µM.
(B) Three mice were evaluated for each treatment group and a total of 150200 crypt nuclei were scored for γH2AX positive nuclei in each treatment
group. (C) Small intestines were isolated from treated mice and analyzed by
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Western blotting for Cdk1 (total levels), Cdk1 phosphorylated on tyrosine 15
(pY15) and tubulin. (D) Small intestinal crypts isolated from treated mice
were stained for phistone H3 (pHH3, red) and nuclei (blue, DAPI) and (E) the
number of pHH3 positive cells per 75 crypts was determined. Scale bar = 100
µM. Three mice were analyzed per treatment group. (F) Small intestinal
crypts isolated from treated mice were examined for cleaved caspase-3 (CC3)
(brown) and nuclei (hematoxylin, blue) by IHC. Scale bar = 100 µM. (G) The
number of cells staining positive for CC3 was determined by counting CC3
positive cells in a total of 50 crypts per treatment group (n = 3 mice per
treatment group). Data in panels B, E and G is presented as mean +/- SEM.
Asterisks indicate significantly different by a one-way ANOVA.*p between
0.01 and 0.05; **p between 0.01 and 0.001; ***p< 0.001. Statistical
significance for comparisons between irinotecan and the combination
treatment across genotypes is indicated in supplementary Table S1.
Figure 6. p53 null orthotopic colon tumors lacking basal p21 undergo
profound cell death in response to combination therapy. (A) Parental
HCT116 cells stably expressing click beetle red luciferase (CBRLuc) and
control (Ctrl) shRNAs were either mock irradiated or exposed to 20 J/m 2 UV.
Lysates were prepared and analyzed by Western blotting 24 h later. (B)
Lysates prepared from p53 null HCT116 cells stably expressing CBRLuc and
either Ctrl or p21 specific shRNAs were analyzed by Western blotting. (C) p53
null HCT116 cells stably expressing CBRLuc and Ctrl shRNAs were implanted
into the cecum of immunocompromised mice. One week later, mice were
injected with D-luciferin and subjected to bioluminescence imaging using the
IVIS Lumina system (Caliper). Representative images of mice are shown.
Photon flux is indicated by pseudocolored heatmap and tumor specific
luciferase activity was measured by drawing a rectangular region of interest
(ROI) as indicated (units: photons/sec x 106). (D) Treated mice engrafted
with the indicated HCT116 cell lines were sacrificed and tumors were isolated
and analyzed for pHH3 by immunofluorescence. Total and pHH3 positive cells
were determined in three separate fields per tumor section per treatment
group (n = 3 mice per treatment group). (E) Treated mice engrafted with the
indicated HCT116 cell lines were sacrificed and tumors were isolated and
analyzed by IHC for CC3 (brown) and nuclei were counterstained with
hematoxylin (blue). (F) Total and CC3 positive cells were determined in four
to five separate fields per tumor section per treatment group (n = 3 to 4 mice
per treatment group). Scale bar =100 µM. Data in panels D and E is
presented as mean +/- SEM. Asterisks indicate significantly different by a
one-way ANOVA. *p = 0.01 to 0.05, **p= 0.01 to 0.001.
Figure 7. Model to explain the differential sensitivity of p53 and p21
null cells to DNA damage alone or combined with loss of Chk1
activity. (A) Small intestinal epithelial cells responded to irinotecan by
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activating a p53- dependent response pathway leading to the transcriptional
activation of genes encoding cell cycle arrest (p21 and 14-3-3 ) and
apoptotic (PUMA) proteins. Activation of cyclin- dependent protein kinases
(Cdks) was prevented by at least two mechanisms including p21 binding and
tyrosine phosphorylation (pY). Two pools of p21 were present in these cells
(those that existed prior to irinotecan-treatment (basal or p53-independent,
teal colored) and those that accumulated after irinotecan-treatment (p53induced, salmon colored). Although equivalent levels of DNA damage were
observed in p53 proficient and null cells, only p53 proficient cells underwent
apoptosis, due to the accumulation of cell death proteins such as PUMA. In
p21 null cells, DNA damage failed to efficiently inactivate Cdks due to loss of
p21 (both p53-dependent and –independent pools) and cells did not
efficiently arrest their cell division cycles under these conditions. Higher levels
of DNA damage and therefore apoptosis (p53-dependent) were observed
under these conditions. Cells lacking both p21 and p53 sustain high levels of
DNA damage (due to loss of basal and induced pools of p21) but underwent
less apoptosis (due to loss of p53- dependent apoptosis).
(B) Treating small intestinal epithelial cells with irinotecan followed by a Chk1
inhibitor, resulted in the tyrosine dephosphorylation of Cdks due to the
accumulation of the Cdc25A phosphatase (4). However, both basal and
induced p21 pools were able to maintain low Cdk activity under these
conditions. Thus, Chk1 inhibition did not synergize with irinotecan to induce
more DNA damage in normal intestinal epithelial cells. However, in p53 null
cells treated with the combination therapy, loss of tyrosine phosphorylation
coupled with loss of p21 synergized to induce apoptosis. Finally, levels of
apoptosis were even higher in cells lacking p21 because these cells lack Cdk
tyrosine phosphorylation as well as basal and induced pools of p21.

Supplementary Data:
Supplemental Figure Legends
Figure S1. Impact of p53 and p21 status on response of crypt
epithelial cells in small intestines to various treatment regimens (a)
Lysates prepared from small intestines of treated WT (lanes 1-4) and p21 null
(lanes 5-8) mice and of an untreated p53 null mouse (lane 9) were subjected
to Western blotting with the indicated antibodies. (b) Lysates prepared from
the small intestines of treated WT (lanes 1-4) and p53 null (lanes 5-8) mice
were subjected to Western blotting with the indicated antibodies. (c) Small
intestinal crypts isolated from treated mice of the indicated genotypes were
examined for cleaved PARP by IHC. The number of cells staining positive for
cleaved PARP was determined in 50 crypts per treatment group (n = 3 to 4
mice per treatment group). (d) Small intestinal crypts isolated from treated
mice of the indicated genotypes were examined for cleaved caspase-3 (CC3)
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by IHC. Values for irinotecan and vehicle treated groups were utilized from
figure 2b. The number of cells staining positive for CC3 was determined in a
total of 50 crypts per treatment group (n = 3 to 4 mice per treatment group).
Data is presented as mean +/- SEM in panels c and d. Asterisks indicate
significantly different using a two-tailed T-test. *p between 0.01 and 0.05,
**p between 0.01 and 0.001.
Figure S2. Replication checkpoint compromised in crypt epithelial
cells null for p21. (a) Treated mice of the indicated genotypes were injected
with BrdU 30 min prior to sacrifice. Small intestines were isolated and
analyzed by immunofluorescent staining for BrdU (red). Nuclei (blue) were
stained with DAPI. Scale bar = 100 µM. (b) Percentage of crypt epithelial cells
staining positive for BrdU was determined by scoring 200 to 300 nuclei per
mouse (n = 3 to 4 mice per treatment group). Data is presented as mean +/SEM in panel B. Asterisks indicate significantly different using a two-tailed Ttest, **p = 0.01 to 0.001.
Figure S3. Coincidence of pHH3 and CC3 staining in crypt epithelial
cells of treated mice. (a) Small intestines were isolated from p53 null mice
treated with Irinotecan and UCN-01 and analyzed by immunofluorescent
staining for CC3 (green), pHH3 (red) and nuclei (blue, DAPI). Crypt borders
are demarcated with white dotted lines. Scale bar = 20 µM. (b) Small
intestines were isolated from treated mice as in panel A and the number of
cells co-stained for CC3 and pHH3 were counted in 200-300 crypts per mouse
per treatment group (n = 3 mice per treatment group). Data is presented as
mean +/- SEM. Asterisks indicate significantly different using a two-tailed Ttest, *p = 0.01 to 0.05, **p = 0.01 to 0.001. (c) Small intestinal crypts
isolated from treated mice were examined for pHH3 (red) and nuclei (blue,
DAPI) by immunofluorescent staining. Scale bar = 100 µM. (d) The number of
pHH3 positive cells was determined in 75 crypts per mouse (n = 3 mice per
treatment group). Data is presented as mean +/- SEM. Asterisks indicate
significantly different using a two-tailed T-test, *p = 0.05 to 0.01, ** p =
0.01 to 0.001.
Figure S4. Effects of losing both basal and induced (p53 dependent)
p21 in crypt epithelial cells. (a) Representative image of a small intestinal
crypt from an irinotecan-treated mouse null for both p53 and p21 stained for
γH2AX (brown) and nuclei were counterstained with hematoxylin (blue).
Intensity of staining was graded with 0 (no), 1 (weak), 2 (moderate) and 3
(strong) staining. Scale bar = 50 µM. (b) The grading scale described above
was used to score the intensity of γH2AX staining in 200-300 crypt nuclei in
treated p53/p21 null mice (n = 3 mice per treatment group). (c) Treated
p53/p21 null mice were injected with BrdU 30 min prior to sacrifice. Small
intestines were isolated and analyzed by immunofluorescent staining for BrdU
(red). Nuclei (blue) were stained with DAPI. Scale bar = 100 µM. (d)
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Percentage of crypt epithelial cells staining positive for BrdU was determined
by scoring 200 to 300 nuclei per mouse (n = 3 mice per treatment group).
Data is presented as mean +/- SEM. A significant difference was not observed
between vehicle- and irinotecan-treatment as determined by a two- tailed Ttest. (e) Parental CBRluc expressing HCT116 cells were transfected with
control (Ctrl) shRNA (lane 1) or shRNAs targeting different regions of p21
(lanes 2-5) followed by selection in puromycin. Lysates were prepared and
interrogated by Western blotting. HCT116 cells null for both p21 and 14-3-3σ
were similarly analyzed (lane 6). (f) Parental CBRluc expressing HCT116 cells
were mock transfected (lane 1) or transfected with shRNAs targeting different
regions of p21 (lanes 2-5). Cell lysates were prepared 48h after transfection
and analyzed by Western blotting. Transfection with p21 shRNA #3 was run in
duplicate. HCT116 cells null for both p21 and 14-3-3σ were similarly analyzed
(lane 6).
Table S1: Statistical significance for comparisons between irinotecan
treatment across genotypes and combination treatment across
genotypes in the intestinal crypts. Staining and quantitation of the
markers used was carried out as described in the main figure legends.
Asterisks indicate significantly different as determined by a one-way ANOVA.
*p between 0.01 and 0.05; **p between 0.01 and 0.001; ***p< 0.001. ns=
Not significant as determined by a one- way ANOVA.
Comparisons of irinotecan (black) and combination treatment (grey)
across genotypes

*p between 0.01 and 0.05, **p between 0.01 and 0.001, ***p< 0.001, ns=
not significant

Supplemental Methods
Genotyping Trp53, Cdkn1a mutant mice
To genotype Cdkn1a mutant mice, primers listed by the Jackson
Laboratory were used (IMR8294, IMR8296, and IMR 0845). To genotype
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Trp53 status in the single and double knockout lines, primers listed by the
Jackson Laboratory were used (IMR7777, IMR7778, and IMR8306).

Immunohistochemistry (IHC)
Intestines were washed using a 60 ml syringe (blunt ended 181/2 gauge
needle) filled with phosphate buffered saline (PBS). Intestines were then
rinsed with 10% neutral buffered formalin (NBF), cut open and immobilized
on a petridish with the villi facing upward. After overnight fixation in 10%
NBF, sections starting with stomach and ending with the rectum were
organized into one block by adding 1.5% agarose solution and embedded in
paraffin. All paraffin- embedded 5 µM intestinal sections were baked in an
oven at 65°C for 20 min and then de-paraffinized by immersing in xylene
twice for 5 min each. The sections were then rehydrated by immersing twice
for 2 min each in a decreasing gradient of alcohol (100%, 95% and 70%
ethanol). Endogenous peroxidase activity was removed by incubating sections
in 3% hydrogen peroxide in methanol for 10 min. Antigen retrieval was
carried out by boiling sections in 10 mM sodium citrate pH 6.0 for 30 min and
then by cooling at room temperature (RT) for an additional 30 min. Sections
were blocked with 3% BSA/ 0.1% Tween-20/PBS (blocking solution) for 30
min. All primary and secondary antibodies were diluted in blocking solution.
Sections were then incubated with either serine 139 phosphorylated H2AX
antibody (1:100, #9718) or cleaved caspase-3 antibody (1: 75) for 2h at RT
and cleaved PARP (1:100) overnight at 4˚C (Cell Signaling Technology)
followed by incubation with the secondary polymer-HRP anti-rabbit antibody
(Dako). Positive staining was visualized using the HRP substrate
Diaminobenzidine (Zymed). Sections were counterstained with Hematoxylin
(Zymed) and then dehydrated through an increasing gradient of alcohol
(70%, 95% and 100%) and immersed in xylene. Sections were mounted
using cytoseal-60 (Richard Allan Scientific).

Immunofluorescent (IF) staining
Intestinal sections were redehydrated as described for IHC. Antigen
retrieval was carried out as described above except 1X Rodent Decloaker
(Biocare Medical) was used. Sections were then blocked in hydrogen peroxide
(Dako) for 10 min and protein block (Dako) for 1h. Sections were incubated
with the following primary antibodies diluted in antibody diluents (Dako):
Geminin (1:350, Santa Cruz FL-209, 1.5h) and secondary polymer-HRP antirabbit antibody (Dako, 30 min) followed by the fluorescein-conjugated
Tyramide signal amplification system (1:50, Perkin Elmer, 15 min). For BrdU
staining, anti-Brdu antibody was used (1:100, Serotec, OBT0030G) for 1.5h
followed by Cy5-conjugated anti-rat antibody (1:100, Jackson
ImmunoResearch). For co-staining phistone H3 and cleaved caspase-3,
sections were incubated with phosphorylated serine 28 histone H3 (1:1000,
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Sigma-Aldrich) and cleaved caspase-3 (1:100, Cell Signaling Technology)
overnight at 4˚C. The following secondary antibodies were applied for 1h:
FITC- conjugated anti-rabbit antibody (1:400, Alexis Biochemicals) for
cleaved caspase-3 and Texas- red-conjugated anti-rat antibody (1:400, Alexis
Biochemicals) for phistone H3. All fluorescently labeled sections were
counterstained with 4'-6-Diamidino-2-phenylindole (DAPI) using the ProLong
Gold antifade-DAPI reagent (Invitrogen).

Quantitation of positive staining
Positive staining for the initial set of treatments was measured by an
investigator who was blinded to the identity of the treatment groups. For
analysis of positive staining in irinotecan- UCN-01-Purvalanol/ vehicle treated
groups; two investigators who were blinded to the identity of treatment
groups carried out measurements. All tumor treatment sets that carried
positive phistone H3 and cleaved caspase-3 staining were analyzed by an
investigator who was blinded to the identity of the treatment groups.

Cell culture and shRNA transfection
HCT116 cells (parental, p53 null and p21/14-3-3σ null) 2,3, were
cultured and maintained in McCoy’s 5A media (GIBCO). Sequences encoding
CBRLuc were isolated from pCBRLuc basic vector (Promega) and sequences
encoding EGFP were isolated from pEGFP (Clonetech). PCR strategies were
used to clone CBRLuc and EGFP sequences into Nde I/Not1 digested pcDNA
3.1 (Promega) to create an expression plasmid encoding the CBRLuc-EGFP
fusion protein. HCT116 parental and derivative lines were transfected with 5
µg of pcDNA-CBRLuc-EGFP and 12 µl of Lipofectamine 2000 (Invitrogen). 24h
later, parental HCT116 cells were selected in media containing 10 µg/ml
zeocin, and p53 null HCT116 cells were placed in media containing 50 µg/ml
zeocin. ~30 drug resistant colonies were isolated and luciferase expression
was screened by adding D-luciferin (1:100 dilution of a 30 mg/ml stock,
Biosynth) followed by imaging using an IVIS Lumina (Caliper). For shRNA
transfections, pLKO.1 plasmids carrying three different shRNA sequences
were tested for their efficiency in knocking down p21 expression (shRNA #1:
GAGCGATGGAACTTCGACTTT, shRNA#2: GCTGATCTTCTCCAAGAGGAA,
shRNA#3: CGCTCTACATCTTCTGCCTTA). Since shRNA#3 was the most
effective in knocking down p21 expression, it was used to carry out stable
transfections. shRNA targeting firefly luciferase (AGTACTTCGAAATGTCCGTT)
was used as the control. To generate stable cell lines, cells were transfected
with 3 µg of pLKO.1 (shRNA#3 or ctrl shRNA) plasmid and 10 μl
Lipofectamine 2000 (Invitrogen). 48h later, cells were placed in media
containing 2 µg/ml puromycin. ~30 colonies were screened for p21
knockdown by Western blotting.
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Tumor cell injections and bioluminescence imaging
HCT116 tumor cell injections were carried out as described previously
, except a 29 gauge 1/2 ″ insulin syringe (Terumo) was used and 1.3x10 6
cells resuspended in 30 µl DMEM were injected per site, and each mouse
received injections at 2 distant sites in the cecum. A week after implantation,
mice were injected with 150 mg/kg D-luciferin (Biosynth) and imaged on an
IVIS Lumina (Caliper). Tumors from both sites were washed in PBS, and
tumors from one site were
4

formalin fixed and paraffin embedded whereas tumors from the other site
were rapid frozen on dry ice.

Western blotting
Intestinal tissue (1.5 cm) was washed in PBS, finely sliced and
resuspended in 700 µl mammalian cell lysis buffer (MCLB) and homogenized
as previously described 5. HCT116 cells cultured on 10-cm plates were lysed
in MCLB. Tissue and cell lysates were rocked for 20 min at 4°C and cleared at
14,000 rpm for 10 min. Proteins were resolved by SDS-polyacrylamide gel
electrophoresis. 150 µg of total protein was loaded per lane and transferred
to nitrocellulose membranes (0.45 micron, Nitro Bind, GE Scientific). Blots
were blocked overnight in 5% non fat dry milk dissolved in Tris-buffered
saline/ 0.2% Tween-20. Blots were probed with the primary antibodies as
indicated in the main methods. All primary antibodies were added to 5% milk
dissolved in Tris-buffered saline/ 0.2% Tween-20. Secondary antibodies
(Jackson ImmunoResearch) were diluted 1:30,000 in Tris-buffered
saline/Tween-20. Blots were visualized using ECL Western blotting reagent
(GE Scientific).

Statistical analysis
All graphical data is presented as mean +/- SEM. Statistically
significant differences between various treatments are represented by
brackets. Statistical analysis as indicated in figure legends was carried out
either using a two-tailed t-test or one-way ANOVA using Dunnett’s multiple
comparison post test for H2AX, pHH3, CC3 and Tukey’s multiple comparison
post test for Geminin counting, with alpha value set to 0.05.
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